|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anders C and Carey LA: Understanding and
treating triple-negative breast cancer. Oncology (Williston Park).
22:1233–1243. 2008.PubMed/NCBI
|
|
3
|
Yadav BS, Sharma SC, Chanana P and Jhamb
S: Systemic treatment strategies for triple-negative breast cancer.
World J Clin Oncol. 5:125–133. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garcia-Becerra R, Santos N, Diaz L and
Camacho J: Mechanisms of resistance to endocrine therapy in breast
cancer: Focus on signaling pathways, miRNAs and genetically based
resistance. Int J Mol Sci. 14:108–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gradishar WJ, Anderson BO, Balassanian R,
Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A,
Giordano SH, et al: NCCN guidelines insights breast cancer, version
1.2016. J Natl Compr Canc Netw. 13:1475–1485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schiff R, Massarweh S, Shou J and Osborne
CK: Breast cancer endocrine resistance: How growth factor signaling
and estrogen receptor coregulators modulate response. Clin Cancer
Res. 9:447S–454S. 2003.PubMed/NCBI
|
|
8
|
Sankhala KK, Mita MM, Mita AC and Takimoto
CH: Heat shock proteins: A potential anticancer target. Curr Drug
Targets. 12:2001–2008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
da Silva VC and Ramos CH: The network
interaction of the human cytosolic 90 kDa heat shock protein Hsp90:
A target for cancer therapeutics. J Proteomics. 75:2790–2802. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang H and Burrows F: Targeting multiple
signal transduction pathways through inhibition of Hsp90. J Mol Med
(Berl). 82:488–499. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chiosis G, Vilenchik M, Kim J and Solit D:
Hsp90: The vulnerable chaperone. Drug Discov Today. 9:881–888.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mosser DD and Morimoto RI: Molecular
chaperones and the stress of oncogenesis. Oncogene. 23:2907–2918.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whitesell L, Mimnaugh EG, De Costa B,
Myers CE and Neckers LM: Inhibition of heat shock protein
HSP90-pp60v-src heteroprotein complex formation by benzoquinone
ansamycins: Essential role for stress proteins in oncogenic
transformation. Proc Natl Acad Sci USA. 91:pp. 8324–8328. 1994;
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Supko JG, Hickman RL, Grever MR and
Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as
an antitumor agent. Cancer Chemother Pharmacol. 36:305–315. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caldas-Lopes E, Cerchietti L, Ahn JH,
Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A,
Guo Y, et al: Hsp90 inhibitor PU-H71, a multimodal inhibitor of
malignancy, induces complete responses in triple-negative breast
cancer models. Proc Natl Acad Sci USA. 106:pp. 8368–8373. 2009;
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lundgren K, Zhang H, Brekken J, Huser N,
Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC,
et al: BIIB021, an orally available, fully synthetic small-molecule
inhibitor of the heat shock protein Hsp90. Mol Cancer Ther.
8:921–929. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bao R, Lai CJ, Wang DG, Qu H, Yin L,
Zifcak B, Tao X, Wang J, Atoyan R, Samson M, et al: Targeting heat
shock protein 90 with CUDC-305 overcomes erlotinib resistance in
non-small cell lung cancer. Mol Cancer Ther. 8:3296–3306. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Woodhead AJ, Angove H, Carr MG, Chessari
G, Congreve M, Coyle JE, Cosme J, Graham B, Day PJ, Downham R, et
al: Discovery of
(2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois
oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular
chaperone Hsp90 by fragment based drug design. J Med Chem.
53:5956–5969. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Trepel JB, Neckers LM and Giaccone
G: STA-9090, a small-molecule Hsp90 inhibitor for the potential
treatment of cancer. Curr Opin Investig Drugs. 11:1466–1476.
2010.PubMed/NCBI
|
|
22
|
Eccles SA, Massey A, Raynaud FI, Sharp SY,
Box G, Valenti M, Patterson L, de Haven Brandon A, Gowan S, Boxall
F, et al: NVP-AUY922: A novel heat shock protein 90 inhibitor
active against xenograft tumor growth, angiogenesis, and
metastasis. Cancer Res. 68:2850–2860. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ohkubo S, Kodama Y, Muraoka H,
Hitotsumachi H, Yoshimura C, Kitade M, Hashimoto A, Ito K, Gomori
A, Takahashi K, et al: TAS-116, a highly selective inhibitor of
heat shock protein 90α and β, demonstrates potent antitumor
activity and minimal ocular toxicity in preclinical models. Mol
Cancer Ther. 14:14–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bussenius J, Blazey CM, Aay N, Anand NK,
Arcalas A, Baik T, Bowles OJ, Buhr CA, Costanzo S, Curtis JK, et
al: Discovery of XL888: A novel tropane-derived small molecule
inhibitor of HSP90. Bioorg Med Chem Lett. 22:5396–5404. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Infante JR, Weiss GJ, Jones S, Tibes R,
Bauer TM, Bendell JC, Hinson JM Jr, Von Hoff DD, Burris HA III,
Orlemans EO and Ramanathan RK: Phase I dose-escalation studies of
SNX-5422, an orally bioavailable heat shock protein 90 inhibitor,
in patients with refractory solid tumours. Eur J Cancer.
50:2897–2904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jeong JH, Oh YJ, Lho Y, Park SY, Liu KH,
Ha E and Seo YH: Targeting the entry region of Hsp90's ATP binding
pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide.
Eur J Med Chem. 124:1069–1080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jeong CH, Park HB, Jang WJ, Jung SH and
Seo YH: Discovery of hybrid Hsp90 inhibitors and their
anti-neoplastic effects against gefitinib-resistant non-small cell
lung cancer (NSCLC). Bioorg Med Chem Lett. 24:224–227. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeong JH, Oh YJ, Kwon TK and Seo YH:
Chalcone-templated Hsp90 inhibitors and their effects on gefitinib
resistance in non-small cell lung cancer (NSCLC). Arch Pharm Res.
40:96–105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dai C and Sampson SB: HSF1: Guardian of
proteostasis in cancer. Trends Cell Biol. 26:17–28. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dechow TN, Pedranzini L, Leitch A, Leslie
K, Gerald WL, Linkov I and Bromberg JF: Requirement of matrix
metalloproteinase-9 for the transformation of human mammary
epithelial cells by Stat3-C. Proc Natl Acad Sci USA. 101:pp.
10602–10607. 2004; View Article : Google Scholar : PubMed/NCBI
|
